: The upper airways represent the point of entrance from where Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection spreads to the lungs. In the present work, α-tocopheryl-polyethylene-glycol succinate (TPGS) micelles loaded with cyclosporine A (CSA) were developed for nasal administration to prevent or treat the viral infection in the very first phases. The behavior of the micelles in presence of simulated nasal mucus was investigated in terms of stability and mucopenetration rate, evidencing long-term stability and fast diffusion across the glycoproteins matrix. Moreover, the spray characteristics of the micellar formulation and deposition profile in a silicon nasal model were studied using three nasal spray devices. Results allowed to identify the nasal spray pump (BiVax, Aptar) able to provide the wider and uniform deposition of the nasal cavity. The cyclosporine A micelles antiviral activity against SARS-CoV-2 was tested on the Omicron BA.1 variant using Vero E6 cells with protocols simulating treatment before, during and after the infection of the upper airways. Complete viral inactivation was observed for the cyclosporine-loaded micelles while a very low activity was evidenced for the non-formulated drug, suggesting a synergistic activity of the drug and the formulation. In conclusion, this work showed that the developed cyclosporine A-loaded micellar formulations have the potential to be clinically effective against a wide spectrum of coronavirus variants.

Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2 / Guareschi, Fabiola; Del Favero, Elena; Ricci, Caterina; Cantù, Laura; Brandolini, Martina; Sambri, Vittorio; Nicoli, Sara; Pescina, Silvia; D'Angelo, Davide; Rossi, Irene; Buttini, Francesca; Bettini, Ruggero; Sonvico, Fabio. - In: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. - ISSN 0928-0987. - 193:(2023). [10.1016/j.ejps.2023.106673]

Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2

Guareschi, Fabiola
Writing – Original Draft Preparation
;
Nicoli, Sara
Conceptualization
;
Pescina, Silvia
Methodology
;
D'Angelo, Davide
Investigation
;
Buttini, Francesca
Resources
;
Bettini, Ruggero
Writing – Review & Editing
;
Sonvico, Fabio
Supervision
2023-01-01

Abstract

: The upper airways represent the point of entrance from where Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection spreads to the lungs. In the present work, α-tocopheryl-polyethylene-glycol succinate (TPGS) micelles loaded with cyclosporine A (CSA) were developed for nasal administration to prevent or treat the viral infection in the very first phases. The behavior of the micelles in presence of simulated nasal mucus was investigated in terms of stability and mucopenetration rate, evidencing long-term stability and fast diffusion across the glycoproteins matrix. Moreover, the spray characteristics of the micellar formulation and deposition profile in a silicon nasal model were studied using three nasal spray devices. Results allowed to identify the nasal spray pump (BiVax, Aptar) able to provide the wider and uniform deposition of the nasal cavity. The cyclosporine A micelles antiviral activity against SARS-CoV-2 was tested on the Omicron BA.1 variant using Vero E6 cells with protocols simulating treatment before, during and after the infection of the upper airways. Complete viral inactivation was observed for the cyclosporine-loaded micelles while a very low activity was evidenced for the non-formulated drug, suggesting a synergistic activity of the drug and the formulation. In conclusion, this work showed that the developed cyclosporine A-loaded micellar formulations have the potential to be clinically effective against a wide spectrum of coronavirus variants.
2023
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2 / Guareschi, Fabiola; Del Favero, Elena; Ricci, Caterina; Cantù, Laura; Brandolini, Martina; Sambri, Vittorio; Nicoli, Sara; Pescina, Silvia; D'Angelo, Davide; Rossi, Irene; Buttini, Francesca; Bettini, Ruggero; Sonvico, Fabio. - In: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. - ISSN 0928-0987. - 193:(2023). [10.1016/j.ejps.2023.106673]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2967932
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact